Allergan Reaches 52-Week High - Analyst Blog
March 05 2013 - 12:38PM
Zacks
Shares of Allergan, Inc. (AGN) hit a 52-week
high of $109.74 almost at the end of the trading session on Mar 4,
2013. The stock was buoyed by the announcement that it was a step
closer to acquiring MAP Pharmaceuticals, Inc.
(MAPP) following the expiration of the tender offer to purchase the
shares of the latter and withdrawal rights.
With more than 22% year-to-date return, a long-term expected
earnings growth rate of approximately 13.3%, this specialty
pharmaceutical company seems to be an attractive pick for long-term
investors. Average volume of shares traded over the last
three months stands at approximately 1,539K. The company has a
market capitalization of $32.7 billion as of Mar 4.
Growth Drivers
On Jan 22, 2013, Allergan announced its intention to acquire MAP
Pharma. The offer price represented a premium of 60% over MAP
Pharmaceuticals’ closing price on that date. The deal is expected
to be worth approximately $958 million.
The acquisition will give Allergan the exclusive rights to migraine
candidate, Levadex, in the US. Levadex is currently under
regulatory review for the treatment of adults suffering from acute
migraine. A response from the US Food and Drug Administration (FDA)
should be out by Apr 15, 2013.
We are positive on Allergan’s decision to buy MAP Pharmaceuticals.
Levadex’ approval would be a major boost for Allergan and will
complement the company’s portfolio, which includes Botox
(onabotulinumtoxinA). Botox is indicated for several indications
including the treatment of chronic migraine headache.
We remind investors that in Jan 2013, the FDA approved Botox for
the treatment of patients suffering from overactive bladder (OAB)
with symptoms of urge urinary incontinence, urgency and frequency,
which was a major boost for the company.
Allergan is looking to sell the obesity intervention segment, which
has performed disappointingly for some quarters now and expects to
do the same in the first half of 2013.
Premium Valuation Justified
Allergan currently trades at a forward price-to-equity (P/E) of
23.0x, reflecting a huge premium of 47.9% compared with the
peer group average of 15.55x. On a price-to-sales and price-to-book
basis, the stock is trading at a premium to the peer group average.
The company has a trailing 12-month return on equity (ROE) of
22.7%, which is below its peer group average of 28.2%.
Given the company’s strong fundamentals, the premium valuation is
justified and well supported by its long-term estimated earnings
growth rate of 13.3% compared to the peer group average of
6.2%.
Allergan carries a Zacks Rank #3 (Hold). Right now, Eli
Lilly and Company (LLY) and Shire plc
(SHPG) look more attractive in the pharma space with a Zacks Rank
#2 (Buy).
ALLERGAN INC (AGN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
(MAPP): Get Free Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Apr 2024 to May 2024
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From May 2023 to May 2024